Literature DB >> 22469071

Review article: fructose in non-alcoholic fatty liver disease.

Y Yilmaz1.   

Abstract

BACKGROUND: The role of excess fructose intake in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) has recently received increasing attention, but the pathophysiology of this relationship has been only partly elucidated. AIM: To provide an overview of the potential role played by fructose in the pathogenesis of NAFLD by focusing on both indirect and direct harmful effects.
METHODS: Experimental and clinical studies which investigated the relation of fructose with NAFLD are reviewed.
RESULTS: Several factors may potentially contribute to fructose-induced NAFLD, including the induction of the metabolic syndrome, copper deficiency, bacterial translocation from the gut to the liver, the formation of advanced glycation endproducts and a direct dysmetabolic effect on liver enzymes.
CONCLUSIONS: Experimentally-increased fructose intake recapitulates many of the pathophysiological characteristics of the metabolic syndrome in humans, which may in turn lead to NAFLD. However, the majority of experimental studies tend to involve feeding excessively high levels of fructose (60-70% of total energy intake) which is not reflective of average human intake. Hopefully, the combination of in vivo, in vitro and genetic research will provide substantial mechanistic evidence into the role of fructose in NAFLD development and its complications.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22469071     DOI: 10.1111/j.1365-2036.2012.05080.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  22 in total

1.  Copper modulates sex-specific fructose hepatoxicity in nonalcoholic fatty liver disease (NALFD) Wistar rat models.

Authors:  Austin Morrell; Brian P Tripet; Brian J Eilers; Megan Tegman; Damon Thompson; Valérie Copié; Jason L Burkhead
Journal:  J Nutr Biochem       Date:  2019-12-16       Impact factor: 6.048

Review 2.  Role of the diet as a link between oxidative stress and liver diseases.

Authors:  Teresa Arrigo; Salvatore Leonardi; Caterina Cuppari; Sara Manti; Angela Lanzafame; Gabriella D'Angelo; Eloisa Gitto; Lucia Marseglia; Carmelo Salpietro
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

3.  Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.

Authors:  Savannah Tallino; Megan Duffy; Martina Ralle; María Paz Cortés; Mauricio Latorre; Jason L Burkhead
Journal:  J Nutr Biochem       Date:  2015-05-15       Impact factor: 6.048

Review 4.  Potential link between excess added sugar intake and ectopic fat: a systematic review of randomized controlled trials.

Authors:  Jiantao Ma; Micaela C Karlsen; Mei Chung; Paul F Jacques; Edward Saltzman; Caren E Smith; Caroline S Fox; Nicola M McKeown
Journal:  Nutr Rev       Date:  2015-10-29       Impact factor: 7.110

Review 5.  Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases.

Authors:  Alejandro Gugliucci
Journal:  Adv Nutr       Date:  2017-01-17       Impact factor: 8.701

6.  Vitamin E Ameliorates Lipid Metabolism in Mice with Nonalcoholic Fatty Liver Disease via Nrf2/CES1 Signaling Pathway.

Authors:  Wenxi He; Yanjiao Xu; Xiuhua Ren; Dong Xiang; Kai Lei; Chengliang Zhang; Dong Liu
Journal:  Dig Dis Sci       Date:  2019-05-10       Impact factor: 3.199

Review 7.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.

Authors:  Ffolliott M Fisher; Patricia C Chui; Imad A Nasser; Yury Popov; Jeremy C Cunniff; Thomas Lundasen; Alexei Kharitonenkov; Detlef Schuppan; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Gastroenterology       Date:  2014-07-30       Impact factor: 22.682

9.  Pathophysiology of NASH: perspectives for a targeted treatment.

Authors:  Fabio Marra; Sophie Lotersztajn
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 10.  Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?

Authors:  Sandeep K Mallipattu; Jaime Uribarri
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.